Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, today announced the addition of over $150 million in capital committed as part of its Series C Financing, bringing the total Series C round to over $430 million. Proceeds from the financing will support the clinical translation of Kriya’s broad pipeline of gene therapies and continued scaling of its engineering, computational and manufacturing platforms. Since its founding in October 2019, Kriya has raised over $600 million in committed capital —and with this financing, Kriya’s cash runway is anticipated to run into late 2026.